TOP3 hemostotting drug injections are selling out to shock the first review

On January 27th, Chengdu Bett Pharmaceuticals announced the listing application for class 4 imitation of amino acid injection and obtained CDE acceptance.
meters of intranet data show that in the first half of 2020 in China's public medical institutions terminal hemostamine drug type TOP20, ammonia cyclic acid ranked third, the growth rate in the last two years has remained at about 7% to 8.
currently no enterprise evaluation of the product, Bett is expected to impact the first review.
Figure 1: Chengdu Bett Pharmaceuticals' ammonia cyclic acid injection registration source: CDE official website Figure 2: Sales of ammonia cyclic acid Source: Minet China's public medical institutions terminal competition pattern ammonia cyclic acid is a classic anti-hematology drug, currently in the surgical trauma of artificial joint replacement is an essential perioperative drug. according to
meters of intranet data, since 2018 in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminals, sales of amino acid has exceeded 800 million yuan, the first half of 2020 ranked in top3 varieties.
the current market of amino acid-related products involving capsules, injections and tablets, of which injection sales accounted for the largest proportion.
from the enterprise structure, injection TOP4 enterprises involved in Chongqing Laimei Pharmaceuticals, Changchun Tiancheng Pharmaceuticals, Shanxi Pude Pharmaceuticals and Hunan Dongting Pharmaceuticals, the first half of 2020 market share of more than 10%.
Figure 3: Ammonia cyclic acid-related product consistency evaluation source: Milnet consistency evaluation database at present, the variety has no enterprise evaluation.
Declared ammonia cyclic acid injection consistency evaluation supplementary application of 3 enterprises, are in the review and approval, and The pharmaceutical industry according to the new classification of the declaration listed, approved as the same review, from the declaration time to see 4 enterprises not far apart, the last who wins and who loses, we wait for the results. Form
1: 2021 to date, the product situation of the company declared to be listed source: Minet MED2.0 China Drug Review Database 2021 to date, Chengdu Bett Pharmaceuticals has four high-end generic drugs declared on the market, involving blood and hematosage drugs, digestive and metabolic drugs and respiratory drugs.
: CDE official website, MiNet database review data statistics as of January 28, 2021, if there are errors, please point out.